Merck and Endocyte's ovarian cancer drug fails in trial
(Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.
The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.
An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.
(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
- U.S. man sues soccer star Cristiano Ronaldo over CR7 trademark
- Moscow fights back after sanctions; battle rages near Ukraine crash site |
- Netanyahu vows to complete Gaza tunnels destruction |
- Argentina defaults but investors see eventual deal possible |
- Obama to Republicans: ‘Stop just hatin’ all the time’